SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and…

Telix Pharmaceuticals Ltd · 6-K filed Jul 21, 2026 at 07:06 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jul 21, 2026 at 07:06 ET

Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and +7% QoQ, driven by Precision Medicine (+30% YoY). FY2026 revenue guidance is tracking at the upper end of US$950M-$970M, with total 2026 revenue and other income expected to exceed US$1B including a US$40M non-refundable payment from Regeneron. The company also announced a strategic collaboration with Regeneron, a US$600M convertible bond refinancing extending maturities, and FDA alignment to advance the ProstACT Phase 3 trial of TLX591-Tx.

  • Q2 2026 group revenue of US$247M, up 21% YoY and 7% QoQ
  • Precision Medicine revenue of US$202M, up 30% YoY
  • FY2026 revenue guidance tracking at upper end of US$950M-$970M, plus US$40M Regeneron payment
  • R&D expenditure guidance updated to US$230M-$270M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access